Sherbrooke Park Advisers LLC Acquires New Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Sherbrooke Park Advisers LLC acquired a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the fourth quarter, Holdings Channel reports. The firm acquired 26,230 shares of the company’s stock, valued at approximately $177,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Accel Wealth Management bought a new stake in Recursion Pharmaceuticals during the 4th quarter valued at about $310,000. Rockefeller Capital Management L.P. raised its holdings in shares of Recursion Pharmaceuticals by 323.1% in the 4th quarter. Rockefeller Capital Management L.P. now owns 281,922 shares of the company’s stock valued at $1,906,000 after purchasing an additional 215,283 shares in the last quarter. Institute for Wealth Management LLC. bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $3,928,000. Invesco Ltd. raised its holdings in shares of Recursion Pharmaceuticals by 54.6% in the 4th quarter. Invesco Ltd. now owns 178,619 shares of the company’s stock valued at $1,207,000 after purchasing an additional 63,068 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $23,429,000. Institutional investors own 89.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Morgan Stanley reduced their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Needham & Company LLC reduced their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, May 6th. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $7.60.

Recursion Pharmaceuticals Stock Up 0.9%

Shares of Recursion Pharmaceuticals stock opened at $4.55 on Wednesday. The firm’s 50 day moving average price is $5.28 and its 200-day moving average price is $6.56. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $12.36. The company has a market cap of $1.85 billion, a P/E ratio of -2.97 and a beta of 0.99.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million during the quarter, compared to analysts’ expectations of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.39) EPS. On average, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.